Chemours (NYSE: CC) reported Q1 EPS of $0.98, $0.44 better than the analyst estimate of $0.54. Revenue for the quarter came in at $1.6 billion versus the consensus estimate of $1.46 billion.

GUIDANCE:

The Company is reaffirming its full year 2023 Adjusted EBITDA and Free Cash Flow guidance. The Company expects full year 2023 Adjusted EBITDA to be within the range of $1.20 - $1.30 billion and expects Free Cash Flow of greater than $350 million, inclusive of approximately $400 million of capital expenditures.

Mr. Newman concluded, \"I am proud of the quarter we delivered as we continue to demonstrate the resiliency and growth potential of our portfolio. We are maintaining our guidance range and remain focused on our five key priorities to create long-term shareholder value, even as we closely monitor the ever-changing economic landscape.

For earnings history and earnings-related data on Chemours (CC) click here.